

References

I-136

1. Gravanis I, Tzogani K, Pignatti F, et al. The European medicines agency review of brentuximab vedotin (adctris) for the treatment of adult patients with relapsed or refractory CD30+ hodgkin lymphoma or systemic anaplastic large cell lymphoma: summary of the scientific assessment of the committee for medicinal products for human use. *Oncologist*. January 2016;21(1):102-109.
2. Gandolfi L, Pellegrini C, Zinzani P, et al. Long-term responders after brentuximab vedotin: single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients. *Oncologist*. 2016;21(12):1436-1441.
3. Kuznar W. Brentuximab vedotin improves responses lasting 4 months in cutaneous T-cell lymphoma. *Am Health Drug Benefits*. 2017;10:14-16.
4. Rubio-Gonzalez B, Zain J, Garcia L, Rosen S, Querfeld C. Cutaneous gamma-delta T-cell lymphoma successfully treated with brentuximab vedotin. *JAMA Dermatol*. 2016;152(12):1388-1390.
5. Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and sezary syndrome with variable CD30 expression level: a multi-institution collaborative project. *J Clin Oncol*. 2015;33(32):3750-3761.
6. Jacobsen ED, Sharman JP, Oki Y, Advani RJ, Winter JN, Bello CM, et al. Brentuximab vedotin demonstrates objective responses in phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. *Blood*. 2015;125(9):1394-1402.
7. Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, and Rakhshandara T. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphotoiod papulosis. *J Clin Oncol*. 2015;33(32):3759-3768.
8. Berger GK, McBride A, Lawson S, Royball K, Yun S, Gee K, et al. Brentuximab vedotin for treatment of non-Hodgkin lymphomas: a systematic review. *Crit Rev Oncol Hematol*. 2017;109:42-50.
9. Connors J, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's Lymphoma. *N Engl J Med* 2018;378:331-44.
10. Ramchandren, R., Advani, R. H., Ansel, et.al. Brentuximab vedotin plus chemotherapy in North American subjects with newly diagnosed stage III or IV Hodgkin lymphoma. *Clin Cancer Res*. 2019;25(6):1718-1726.
11. Brentuximab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated date June 1, 2020.
12. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Brentuximab vedotin.

13. Micromedex DrugDex Compendium®. 2023. Brentuximab vedotin.
14. National Comprehensive Cancer Network (NCCN). Brentuximab vedotin. NCCN Drugs and Biologics Compendium®. 2023.
15. Adcetris® (brentuximab vedotin), injection, for intravenous use [package insert]. Seagen Inc. Bothell WA. Revised 06/2023.